These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22836934)

  • 1. [10 years of assessing prevention and early diagnosis programmes by the Federal Joint Committee of Germany - a methodological analysis].
    Bertelsmann H; Perleth M; Matthias K
    Gesundheitswesen; 2013 Jan; 75(1):7-12. PubMed ID: 22836934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Decision of the Federal Joint Committee on screening for chorionicity - benefit assessment in the absence of screening studies].
    Schwalm A; Bertelsmann H; Gruber S; Wietschel G; Matthias K
    Gesundheitswesen; 2013 Jan; 75(1):13-21. PubMed ID: 22847814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From evidence assessments to coverage decisions?: the case example of glinides in Germany.
    Kreis J; Busse R
    Health Policy; 2012 Jan; 104(1):27-31. PubMed ID: 22136812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].
    Krauth C; John J; Aidelsburger P; Brüggenjürgen B; Hansmeier T; Hessel F; Kohlmann T; Moock J; Rothgang H; Schweikert B; Seitz R; Wasem J;
    Gesundheitswesen; 2008 Jun; 70(6):e1-16. PubMed ID: 18661452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [IGeL - a questionable debate].
    Schaefer C
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(7):540-1. PubMed ID: 22981030
    [No Abstract]   [Full Text] [Related]  

  • 8. [Closing evidence gaps].
    Lange S
    Z Evid Fortbild Qual Gesundhwes; 2011; 105(9):652-6. PubMed ID: 22152422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The periodic health examination: from law to the directive of the German Federal Joint Committee (G-BA)].
    Perleth M; Matthias K
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(4):192-5. PubMed ID: 24889707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany.
    Schaufler TM; Wolff M
    Appl Health Econ Health Policy; 2010; 8(3):191-202. PubMed ID: 20408603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Does a gain in knowledge with no medical consequences trigger statutory health insurance coverage obligation?].
    Wejda S
    Z Evid Fortbild Qual Gesundhwes; 2011; 105(7):531-3. PubMed ID: 21958618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Decision-analytical modelling of costs per QALY in the context of the German Social Law].
    Rogowski WH; Landauer M; John J
    Gesundheitswesen; 2009 Nov; 71(11):739-50. PubMed ID: 19551622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The relevance of quality of life for the work of the Federal Joint Committee].
    Klakow-Franck R
    Z Evid Fortbild Qual Gesundhwes; 2014; 108(2-3):151-6. PubMed ID: 24780714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ["Deficiencies in the mandatory health insurance system"--possibilities and limits of medical expert assessment].
    Mayer ED; Boukamp K; Zink J; Simoes E; Schwoerer P
    Gesundheitswesen; 2000 Oct; 62(10):538-46. PubMed ID: 11103565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Preventive medicine: costs and responsibilities of insurance companies].
    Brunner HH
    Praxis (Bern 1994); 1998 Jan; 87(3):57-60, 62-3. PubMed ID: 9492587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Routine skin cancer screening in Germany: First data on the impact on health care in dermatology.
    Augustin M; Blome C; Rustenbach SJ; Reusch M; Radtke M
    J Dtsch Dermatol Ges; 2010 Sep; 8(9):674-80. PubMed ID: 20529170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of health care--a matter of discussion in Germany.
    Porzsolt F; Ackermann M; Amelung V
    BMC Health Serv Res; 2007 Jan; 7():1. PubMed ID: 17199886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mammography screening in Germany: how, when and why?].
    Bick U
    Rofo; 2006 Oct; 178(10):957-69. PubMed ID: 17021975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Amendment of tuberculosis prevention law and prospect of tuberculosis control program].
    Ushio M
    Kekkaku; 2005 Jul; 80(7):541-6. PubMed ID: 16167781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.